Abstract
The term post-marketing surveillance is a term which should be applied to all forms of monitoring marketed drugs for all aspects of their potential to produce adverse reactions.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Griffin J P and D’ Arcy P F (1981) Adverse Reactions to Drugs - The Information Lag in Side Effects of Drugs Annual No 5, Edited N M G Dukes Excerpta Medica Amsterdam (in press).
Laufer R D (1980) The Medical Literature as an Adverse Drug Reaction Warning System. Appendix VI of “Report of Joint Commission on Prescription Drug Use”(USA)
Watkins S M and Griffin J P (1978) High Incidence of Vincristine- induced Neuropathy in Lymphomas. Br Med J 1, 610–612.
Williams J R B, Griffin J P and Parkins A (1976) Effect of Concomitantly Administered Drugs on the Control of Long Term Anticoagulant therapy. Quart J Med 177 63–73.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1981 Springer Science+Business Media New York
About this chapter
Cite this chapter
Griffin, J.P. (1981). Post-Marketing Surveillance. In: Wardell, W.M., Velo, G. (eds) Drug Development, Regulatory Assessment, and Postmarketing Surveillance. NATO Advanced Study Institutes Series, vol 39. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-4055-3_30
Download citation
DOI: https://doi.org/10.1007/978-1-4684-4055-3_30
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-4057-7
Online ISBN: 978-1-4684-4055-3
eBook Packages: Springer Book Archive